Victoza is Novo Nordisk's brand of liraglutide for type 2 diabetes, the second GLP-1 RA approved in the U.S. (after Byetta). Generic liraglutide has been sold in the U.S. since 2024.
At a glance
- Generic name: liraglutide
- Manufacturer: Novo Nordisk
- List price: not re-checked in October 2026; see the manufacturer's pricing page
- Lower-cost option: generic liraglutide (sold in the U.S. since 2024)
FDA-approved indications
- Type 2 diabetes (2010)
- CV risk reduction in T2D + CVD (2017) — basis: LEADER
Standard dosing
- Start: 0.6 mg daily × 1 wk
- Then 1.2 mg, then 1.8 mg if needed